News

Shionogi To Present New Data on FETROJA® (Cefiderocol) at IDWeek 2020

Shionogi Announces Publication of Two Studies in the Lancet Infectious Diseases Highlighting the Efficacy and Safety of Fetroja® (Cefiderocol) for the Treatment of Infections Due To Aerobic Gram-Negative Bacteria in Adults With Limited Treatment Options

Shionogi Announces Publication of a New Systematic Review in Chest Highlighting the Importance of Early, Appropriate Therapy To Improve Meaningful Outcomes Like Mortality in Patients With Severe Bacterial Infections

Shionogi Announces FDA Approval of FETROJA® (Cefiderocol) for the Treatment of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

Shionogi Granted New Technology Add-On Payment for Fetroja® (Cefiderocol) by CMS

New AMR Action Fund steps in to save collapsing antibiotic pipeline with pharmaceutical industry investment of US$1 billion.

FDA Accepts Shionogi’s Supplemental New Drug Application with Priority Review for FETROJA® (cefiderocol) for the Treatment of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

Shionogi Accelerates Development of Potential COVID-19 Treatments and Vaccine

Shionogi’s FETROJA® (cefiderocol) Now Available for the Treatment of Complicated Urinary Tract Infections in the U.S.